15:40:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-29 Kvartalsrapport 2023-Q2
2023-03-27 Ordinarie utdelning FARON 0.00 EUR
2023-03-24 Årsstämma 2023
2023-03-03 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-07-07 Extra Bolagsstämma 2022
2022-04-25 Ordinarie utdelning FARON 0.00 EUR
2022-04-22 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-26 Ordinarie utdelning FARON 0.00 EUR
2021-04-23 Årsstämma 2021
2021-03-25 Bokslutskommuniké 2020
2020-05-14 Ordinarie utdelning FARON 0.00 EUR
2020-05-13 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019


ListaFirst North Finland
Faron Pharmaceuticals är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.
2022-05-04 12:15:00

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Grant of options

Company announcement, 04 May 2022 at 1:15 PM (EEST) 11:15 AM (BST) / 6:15 AM (EDT)

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the Company's board has confirmed the grant of a total of 497,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019 (including its UK and US sub plans). The Options have been allocated under the Share Option Plan 2019 and are exercisable between 24 March 2023 and 24 March 2027, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan and the UK sub plan is €3.09 per share (£2.57), which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 24 March 2022. The exercise price for Options allocated under the US sub plan is €2.91 per share (£2.43), which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 30 days preceding the allocation date of 24 March 2022. The terms of the Share Option Plan 2019 are available on the Company's website at https://www.faron.com/investors/general-meetings/2020.

The granted Options entitle the option holders to subscribe for a total of 497,000 new ordinary shares in the Company, if exercised in full, and represent 0.9% of the fully diluted ordinary share capital of the Company.

Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs"), scientific advisory board ("SAB") members and Company personnel:

Directors Options granted

Brown Gregory 30,000
Poulos John 30,000
Whitaker Anne 30,000
Fjällskog Marie-Louise 40,000
Hänninen Toni 40,000
Kyttä Kaisa 11,000
Lahtinen Maria 30,000
Total PDMRs 121,000

SAB member
Curiel Tyler 10,000

Jalkanen Sirpa* 10,000
Knowles Jonathan 10,000
Total SAB members 30,000
*Jalkanen Sirpa is a person closely associated ("PCA") to
Jalkanen Markku, Chief Executive Officer of the Company

Total Company personnel 256,000

For more information please contact:

Media / Investor Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications



Phone: +1 (610) 529-6219

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville


Phone: +44 (0)20 3709 5700

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

of a
pursuant to
19(1) of
(EU) No.
1 Details of the person
discharging managerial
closely associated
a. Name a) Brown Gregory

b) Fjällskog Marie

c) Hänninen Toni 

d) Kyttä Kaisa

e) Lahtinen Maria

f) Jalkanen Sirpa

g) Poulos John

h) Whitaker Anne
2 Reason for notification
a. Position/Status Person discharging
on closely
b. Initial notification/ Initial notification

3 Details of the issuer,
emission allowance market
participant, auction
platform, auctioneer or
auction monitor
a. Name Faron
Pharmaceuticals Oy
b. LEI 7437009H31TO1DC0EB42
4 Details of the
transaction(s): section to be
repeated for (i) each type of
instrument; (ii) each type of
transaction; (iii) each date;
and (iv) each place where
transactions have been
a. Description of the financial Options over
instrument, type of ordinary shares
instrument ISIN: FI4000153309
Identification Code
b. Nature of the transaction Grant of options
made under the Faron
Share Option Plan
2019 main, UK and US
sub plans
exercisable at€3.09
per ordinary share
and at €2.91 per
ordinary share under
the US sub plan.
c. Price(s) and volume(s)
Price(s) Volume(s)
Nil a) 30,000

b) 40,000

c) 40,000

d) 11,000

e) 30,000

f) 10,000

g) 30,000

h) 30,000

d. Aggregated information 221,000 options

- Aggregated Volume Nil

- Price
e. Date of the transaction 03 May 2022
f. Place of the transaction Turku